Ken Kato
MD, PhD
Chief, Division of Gastrointestinal Medical Oncology
👥Biography 个人简介
Ken Kato at the National Cancer Center Hospital Japan has been a pivotal investigator in landmark esophageal cancer immunotherapy trials. He contributed to KEYNOTE-811 establishing pembrolizumab combined with trastuzumab and chemotherapy for HER2-positive gastroesophageal junction adenocarcinoma. He also contributed to KEYNOTE-590 defining pembrolizumab plus chemotherapy for esophageal squamous cell carcinoma.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Ken Kato 的研究动态
Follow Ken Kato's research updates
留下邮箱，当我们发布与 Ken Kato（National Cancer Center Hospital）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment